Abstract
<i>Background: </i>Since December 2019, the COVID-19 pandemic has caused the dead of 1 million people, from these critically ill patients have an increased risk of bacteremia. <i>Material and Methods: </i>This observational, retrospective, single-center study included 129 critically ill COVID-19 patients with a bacteremia. We studied the clinical characteristics, comorbidities, hospital and intensive care unit length of stay, days on invasive mechanical ventilation, maximum dose of norepinephrine and mortality. <i>Results: </i>From 129 patients were reported 17 patients (13.2%) with bacteremia. 35.3% were cataloged as a primary bacteremia. The source of secondary bacteremia was a ventilator associated pneumonia in 81.8%, central line-associated blood stream infection in 18.1% and urinary catheter infection in 9%. The patients with bacteremia, had a hospitalization stay of 23 days Vs. 20.5 days in the patients without bacteremia (p=0.19); 18 Vs. 13.5 days in the ICU (p=0.061); 15 Vs 11 days on IMV (p=0.053) and a maximum dose of norepinephrine of 0.28 Vs. 0.11 mcg/kg/min (p=0.02). We reported a 14.8% of mortality in patients with bacteremia vs. 12.7% in patients without bacteremia, odds ratio of 0.87 (p=0.75). <i>Conclusion: </i>Critically ill COVID-19 patients and bacteremia tend to increase the length of stay in the ICU and days on IMV with no change in mortality.
Highlights
Since December 2019, the COVID-19 pandemic has affected more than 42 million people and caused the death of approximately 164 million people
Secondary bacteremia was reported in 64.7% (n=11) of the patients; where the most common pathogens where Pseudomonas aeruginosa and Enterococcus faecalis (4 patients), Staphylococcus aureus (3 patients), Stenotrophomonas maltophilia, Enterococcus faecium, Escherichia coli, and Klebsiella pneumoniae (1 patient each)
We describe the clinical characteristics of COVID-19 patients hospitalized in intensive care unit (ICU) with or without a bacteremia and their clinical relevance
Summary
Since December 2019, the COVID-19 pandemic has affected more than 42 million people and caused the death of approximately 164 million people. Since December 2019, the COVID-19 pandemic has caused the dead of 1 million people, from these critically ill patients have an increased risk of bacteremia. We studied the clinical characteristics, comorbidities, hospital and intensive care unit length of stay, days on invasive mechanical ventilation, maximum dose of norepinephrine and mortality. The patients with bacteremia, had a hospitalization stay of 23 days Vs. 20.5 days in the patients without bacteremia (p=0.19); 18 Vs. 13.5 days in the ICU (p=0.061); 15 Vs 11 days on IMV (p=0.053) and a maximum dose of norepinephrine of 0.28 Vs. 0.11 mcg/kg/min (p=0.02). Conclusion: Critically ill COVID-19 patients and bacteremia tend to increase the length of stay in the ICU and days on IMV with no change in mortality
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
